ES2572915T3 - Nanopartículas conjugadas a un agente antinucleolina - Google Patents
Nanopartículas conjugadas a un agente antinucleolina Download PDFInfo
- Publication number
- ES2572915T3 ES2572915T3 ES12730288.3T ES12730288T ES2572915T3 ES 2572915 T3 ES2572915 T3 ES 2572915T3 ES 12730288 T ES12730288 T ES 12730288T ES 2572915 T3 ES2572915 T3 ES 2572915T3
- Authority
- ES
- Spain
- Prior art keywords
- gro
- human
- antinucleolin
- nucleolin
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Ceramic Engineering (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Composición, que comprende un agente antinucleolina conjugado a nanopartículas, en la que las nanopartículas no son magnéticas, ni de óxido de hierro, ni de poliacrilamida, y en la que las nanopartículas comprenden al menos un miembro seleccionado del grupo que consiste en oro, platino, iridio y paladio, y en la que el agente antinucleolina comprende: a) un oligonucleótido antinucleolina; y/o b) un anticuerpo; y/o c) una proteína de reconocimiento de nucleolina; y/o d) un GRO (oligonucléotido rico en guanosina).
Description
Las Figuras 13A y B muestran la biodistribución de AS1411-GNP-Cy5: los ratones fueron tratados, sacrificados y se fotografiaron los órganos (A) y se examinaron para analizar la fluorescencia (B).
[0026] La presente invención hace uso del descubrimiento de que los agentes antinucleolina, conjugados a partículas, tales como aptámero conjugado a nanopartículas de oro, tienen un efecto antiproliferativo sobre el cáncer y tumores. Además, el aptámero conjugado a nanopartículas de oro en particular, tiene un efecto antiproliferativo 10 similar o mayor que el aptámero (oligonucleótido antinucleolina) por sí solo, demostrando efectos similares a solo de 1/10 a 1/100 de la dosis. Además, estos mismos agentes, que tienen preferiblemente un colorante fluorescente conjugado a la partícula o unida al agente antinucleolina, también se pueden usar tambbién como agentes de obtención de imágenes, tanto in vivo como ex vivo.
15 [0027] Los agentes antinucleolina incluyen (i) aptámeros, tales como GRO; (ii) anticuerpos antinucleolina; y (iii) proteínas que reconocen nucleolina. Ejemplos de aptámeros incluyen oligonucleótidos ricos en guanosina (GRO). Ejemplos de oligonucleótidos y ensayos adecuados se proporciona también en Miller et al. [7]. Las características de GRO incluyen:
(1) que tienen al menos 1 motivo GGT, 20 (2) que tienen preferiblemente 4-100 nucleótidos, aunque GRO que tienen muchos más nucleótidos son posibles,
(3) que tienen opcionalmente modificaciones químicas para mejorar la estabilidad.
[0028] Los GRO especialmente útiles forman estructuras de cuarteto de G, tal como se indica por un perfil de desnaturalización/renaturalización térmica reversible a 295 nm [6]. Los GRO preferidos también compiten con un 25 oligonucleótido de telómero para la unión a una proteína celular diana en un ensayo de desplazamiento por movilidad electroforética [6]. En algunos casos, la incorporación de los nucleótidos GRO en secuencias de ácidos nucleicos más grandes puede ser ventajosa; por ejemplo, para facilitar la unión de un ácido nucleico de GRO a un sustrato sin desnaturalizar el sitio de unión a nucleolina. Los ejemplos de oligonucleótidos se muestran en la Tabla 1; los oligonucleótidos preferidos incluyen las SEQ ID NOs: 1-7; 9-16; 19-30 y 31 de la Tabla 1. 30 Tabla 1. Gros no antisentido que se unen nucleolina y controles que no se unen1,2,3 .
- GRO
- Secuencia SEQ ID NO:
- GRO29A1
- tttggtggtg gtggttgtgg tggtggtgg 1
- GRO29-2
- tttggtggtg gtggttttgg tggtggtgg 2
- GRO29-3
- tttggtggtg gtggtggtgg tggtggtgg 3
- GRO29-5
- tttggtggtg gtggtttggg tggtggtgg 4
- GRO29-13
- tggtggtggt ggt 5
- GRO14C
- ggtggttgtg gtgg 6
- GRO15A
- gttgtttggg gtggt 7
- GRO15B2
- ttgggggggg tgggt 8
- GRO25A
- ggttggggtg ggtggggtgg gtggg 9
- GRO26B1
- ggtggtggtg gttgtggtgg tggtgg 10
- GRO28A
- tttggtggtg gtggttgtgg tggtggtg 11
- GRO28B
- tttggtggtg gtggtgtggt ggtggtgg 12
- GRO29-6
- ggtggtggtg gttgtggtgg tggtggttt 13
- GRO32A
- ggtggttgtg gtggttgtgg tggttgtggt gg 14
- GRO32B
- tttggtggtg gtggttgtgg tggtggtggt tt 15
- GRO56A
- ggtggtggtg gttgtggtgg tggtggttgt ggtggtggtg gttgtggtgg tggtgg 16
- CRO
- tttcctcctc ctccttctcc tcctcctcc 18
- GRO A
- ttagggttag ggttagggtt aggg 19
- GRO B
- ggtggtggtg g 20
- GRO C
- ggtggttgtg gtgg 21
- GRO D
- ggttggtgtg gttgg 22
- GRO E
- gggttttggg 23
- GRO F
- ttggttttgg ggttttggtt 24
- GRO G1
- ggttggtgtg gttgg 25
- GRO H1
- ggggttttgg 26
- GRO I1
- gggttttggg 27
- GRO J1
- ggggttttgg ggttttgggg ttttgggg 28
- GRO K1
- ttggggttgg ggttggggtt gggg 29
- GRO L1
- gggtgggtgg gtgggt 30
- GRO M1
- ttggttttgg ggttttggtt ttttgg 31
5
- GRO N2
- tttcctcctc ctccttctcc tcctcctcc 32
- GRO O2
- cctcctcctc cttctcctcc tcctcc 33
- GRO P2
- tggggt 34
- GRO Q2
- gcatgct 35
- GRO R2
- gcggtttgcg g 36
- GRO S2
- tagg 37
- GRO T2
- ggggttgggg tgtggggttg 38
- 1Indica un buen GRO que se une a nucleolina de membrana plasmática. 2Indica un control de nucleolina (unión a nucleolina no de membrana plasmática). 3Secuencias de GRO sin las denominaciones 1 o 2 tienen cierta actividad antiproliferativa.
[0029] También se puede usar cualquier anticuerpo que se une a nucleolina. En ciertos casos se prefieren anticuerpos monoclonales ya que se unen a epítopos individuales, específicos y definidos. En otros casos, sin embargo, se pueden usar anticuerpos policlonales capaces de interactuar con más de un epítopo en la nucleolina. Muchos anticuerpos antinucleolina están disponibles comercialmente, y de cualquier forma, se fabrican fácilmente. La Tabla 2 enumera unos cuantos anticuerpos antinucleolina disponibles comercialmente.
Tabla 2: Anticuerpos antinucleolina disponibles comercialmente
- Anticuerpo
- Fuente Fuente de antígeno
- Anticuerpo monoclonal (mAb) de ratón p7-1A4
- Developmental Studies Hybridoma Bank Oocitos de Xehopus laevis
- mAb de ratón Sc-8031
- Santa Cruz Biotech Humana
- Ab policlonal (pAb) de cabra Sc-9893
- Santa Cruz Biotech Humana
- pAb de cabra Sc-9892
- Santa Cruz Biotech Humana
- mAb de ratón clon 4E2
- MBL International Humana
- mAb de ratón clon 3G4B2
- Upstate Biotechnology Perro (células MDCK)
- Nucleolina, humana (mAb de ratón)
- MyBioSource Humana
- Antinucleolina-Fosfo purificado, Thr76/Thr84 (mAb de ratón)
- BioLegend Humana
- Anticuerpo policlonal de Nucleolina de Conejo
- Novus Biologicals Humana
- Nucleolina (NCL, C23, FLJ45706)
- US Biological Humana
- FLJ59041, Proteína C23, mAb Mo xHu
- Humana
- Nucleolina (NCL, Nucl, C23, FLJ45706, Proteína C23) Pab Rb xHu
- US Biological Humana
- mAb antinucleolina humana Fosfo-Thr76/Thr84 de ratón, clon 10C7
- Cell Sciences Humana
- Anti-NCL / Nucleolina (pAb)
- LifeSpan Biosciences Humana
- Anticuerpo policlonal de ratón MaxPab purificado de NCL (B02P)
- Abnova Humana
- Anticuerpo policlonal de conejo MaxPab purificado de NCL (D01 P)
- Abnova Humana
- Anticuerpo monoclonal de NCL, clon 10C7 (mAb de ratón)
- Abnova Humana
- Anticuerpo monoclonal de nucleolina (4E2) (mAb de ratón)
- Enzo Life Sciences Humana
- Nucleolina, Anticuerpo Monoclonal de Ratón
- Life Technologies Corporation Humana
- Anticuerpo de NCL (Centro E443) (pAb de conejo)
- Abgent Humana
- Antinucleolina, clon 3G4B2 (mAb de ratón)
- EMD Milipore Humana
- NCL (pAb de conejo)
- Proteintech Group Humana
- Anticuerpo Monoclonal Antinucleolina de Ratón, sin conjugar, clon 3G4B20
- Active Motif Humana
- Nsr1p – monoclonal de ratón
- EnCor Biotechnology Humana
- Nucleolina (mAb de ratón)
- Thermo Scientific Pierce Products Humana
- Anticuerpo [4E2] de nucleolina (mAb de ratón)
- GeneTex Humana
10 [0030] Las proteínas de reconocimiento de nucleolina son proteínas, diferentes de anticuerpos, que se unen específica y selectivamente a nucleolina. Los ejemplos incluyen la proteína ribosomal S3, péptidos F3 de migración tumoral [26, 27] y la miosina H9 (una miosina no muscular que se une la nucleolina de la superficie celular de las células endoteliales en vasos angiogénicos durante la tumorigénesis).
15 [0031] Los agentes antinucleolina se pueden conjugar a partículas fabricadas de una variedad de materiales, materiales sólidos, incluyendo (1) metales y elementos; (2) óxidos; (3) semiconductores; y (4) polímeros. Los
6
Claims (1)
-
imagen1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161492683P | 2011-06-02 | 2011-06-02 | |
US201161492683P | 2011-06-02 | ||
PCT/US2012/040577 WO2012167173A1 (en) | 2011-06-02 | 2012-06-01 | Anti-nucleolin agent-conjugated nanoparticles |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2572915T3 true ES2572915T3 (es) | 2016-06-03 |
Family
ID=46395687
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES15182208.7T Active ES2690557T3 (es) | 2011-06-02 | 2012-06-01 | Nanopartículas conjugadas a un agente antinucleolina |
ES12730288.3T Active ES2572915T3 (es) | 2011-06-02 | 2012-06-01 | Nanopartículas conjugadas a un agente antinucleolina |
ES18185333T Active ES2880291T3 (es) | 2011-06-02 | 2012-06-01 | Nanopartículas conjugadas a un agente antinucleolina |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES15182208.7T Active ES2690557T3 (es) | 2011-06-02 | 2012-06-01 | Nanopartículas conjugadas a un agente antinucleolina |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES18185333T Active ES2880291T3 (es) | 2011-06-02 | 2012-06-01 | Nanopartículas conjugadas a un agente antinucleolina |
Country Status (7)
Country | Link |
---|---|
US (3) | US9452219B2 (es) |
EP (3) | EP3011974B1 (es) |
DK (2) | DK3011974T3 (es) |
ES (3) | ES2690557T3 (es) |
PL (1) | PL3446714T3 (es) |
PT (1) | PT3446714T (es) |
WO (1) | WO2012167173A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7357928B2 (en) | 2002-04-08 | 2008-04-15 | University Of Louisville Research Foundation, Inc. | Method for the diagnosis and prognosis of malignant diseases |
EP2501800A4 (en) | 2009-11-17 | 2013-05-22 | Musc Found For Res Dev | HUMAN MONOCLONAL ANTIBODIES FOR HUMAN NUCLEOLIN |
PL3446714T3 (pl) * | 2011-06-02 | 2021-11-22 | University Of Louisville Research Foundation, Inc. | Nanocząstki sprzężone z cząsteczką skierowaną przeciwko nukleolinie |
KR101596552B1 (ko) * | 2013-02-13 | 2016-02-23 | 중앙대학교 산학협력단 | 금나노입자-앱타머 결합체를 기반으로 하는 단백질 전달체 및 이의 제조 방법 |
CA3020885A1 (en) | 2015-05-05 | 2016-11-10 | Mohammad Tariq MALIK | Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents |
WO2017011411A1 (en) * | 2015-07-10 | 2017-01-19 | Ohio State Innovation Foundation | Methods and compositions relating to anti-nucleolin recombinant immunoagents |
EP3426691A4 (en) | 2016-03-07 | 2019-09-25 | Charlestonpharma, LLC | ANTI-NUCLEOLIN ANTIBODIES |
US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
WO2019079164A1 (en) * | 2017-10-16 | 2019-04-25 | University Of Cincinnati | COMBINATION OF AS1411 AND SAPC-DOPS FOR THE TREATMENT OF MULTIPLE GLIOBLASTOMA |
WO2021050779A2 (en) | 2019-09-10 | 2021-03-18 | University Of Louisville Research Foundation, Inc. | Anti-nucleolin agent-peg-conjugated nanoparticles |
US20210299156A1 (en) * | 2020-03-28 | 2021-09-30 | Qualigen Inc. | Methods of inhibiting or treating coronavirus infection, and methods for delivering an anti-nucleolin agent |
JP7436710B2 (ja) * | 2020-05-19 | 2024-02-22 | アニゲン カンパニー、リミテッド | 新規のヌクレオリン-結合ペプチド及びその用途 |
USD952157S1 (en) | 2020-06-19 | 2022-05-17 | Qualigen Inc. | Whole blood treatment cartridge |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4474892A (en) | 1983-02-16 | 1984-10-02 | Board Of Trustees Of The Leland Stanford Junior University | Two-site immunoassays using monoclonal antibodies of different classes or subclasses and test kits for performing same |
US5169774A (en) | 1984-02-08 | 1992-12-08 | Cetus Oncology Corporation | Monoclonal anti-human breast cancer antibodies |
US4671256A (en) | 1984-05-25 | 1987-06-09 | Lemelson Jerome H | Medical scanning, monitoring and treatment system and method |
US5055459A (en) | 1986-06-30 | 1991-10-08 | Board Of Regents, The University Of Texas | Selective elimination of malignant cells from bone marrow by bis (acyloxy) propylphosphoramidates |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US5223427A (en) | 1987-03-31 | 1993-06-29 | The Scripps Research Institute | Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5192660A (en) | 1989-04-24 | 1993-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | ELISA methods for the determination of human platelet derived growth factor (PDGF) dimer forms present in human tissues and fluids |
US6020145A (en) | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
AU635008B2 (en) | 1989-12-13 | 1993-03-11 | Genelabs Diagnostics Pte Ltd | Analytical apparatus and method for automated blot assay |
US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5736348A (en) | 1990-11-28 | 1998-04-07 | Fundacao Oswaldo Cruz (Fiocruz) | Method for the immunological diagnosis of Chagas' Disease using recombinant antigens |
JPH05244988A (ja) | 1992-03-04 | 1993-09-24 | Green Cross Corp:The | 抗組織因子モノクローナル抗体、及びこれによる免疫抑制剤 |
DK0744958T3 (da) | 1994-01-31 | 2003-10-20 | Univ Boston | Polyklonale antistofbiblioteker |
JPH07242566A (ja) | 1994-03-01 | 1995-09-19 | Kirin Brewery Co Ltd | 免疫抑制剤 |
US5691447A (en) | 1995-03-24 | 1997-11-25 | Tanox Biosystems, Inc. | GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies |
US6096532A (en) | 1995-06-07 | 2000-08-01 | Aastrom Biosciences, Inc. | Processor apparatus for use in a system for maintaining and growing biological cells |
CA2240494C (en) | 1995-12-15 | 2007-03-13 | Lloyd G. Mitchell | Therapeutic molecules generated by trans-splicing |
US6582921B2 (en) * | 1996-07-29 | 2003-06-24 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses thereof |
US5846517A (en) | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
US6048703A (en) | 1996-11-15 | 2000-04-11 | Cephalon, Inc. | Methods for detecting cell apoptosis |
DK0942968T3 (da) | 1996-12-03 | 2008-06-23 | Amgen Fremont Inc | Fuldt humane antistoffer, der binder EGFR |
CA2284084A1 (en) | 1997-03-12 | 1998-09-17 | Institut Pasteur | A novel cell surface receptor for hiv retroviruses, therapeutic and diagnostic uses |
JP2001523977A (ja) | 1997-06-05 | 2001-11-27 | ザ ユニバーシティ オブ テキサス システム ボード オブ リージェンツ | Apaf−1、ced−4ヒト相同体、カスパーゼ−3の活性化因子 |
CA2293632C (en) | 1997-06-12 | 2011-11-29 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
US6339075B1 (en) | 1997-06-30 | 2002-01-15 | The University Of British Columbia | Use of dextran and other polysaccharides to improve mucus clearance |
WO1999006588A1 (en) | 1997-08-04 | 1999-02-11 | The Burnham Institute | A cell-free system of mitochondria-dependent apoptosis, and methods of use thereof |
US6325785B1 (en) | 1997-08-14 | 2001-12-04 | Sherwood Services Ag | Sputum trap manifold with nested caps |
US5925334A (en) | 1997-08-27 | 1999-07-20 | Rubin; Bruce K. | Use of surface active agents to promote mucus clearance |
US5932475A (en) | 1997-12-12 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Human nucleolin-like protein |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
EP1072682A4 (en) | 1998-04-10 | 2005-01-26 | Chugai Pharmaceutical Co Ltd | PROTEIN AND GENE PARTICIPATING IN THE DIFFERENTIATION OF IMMORTALIZED CELLS |
US6306404B1 (en) | 1998-07-14 | 2001-10-23 | American Cyanamid Company | Adjuvant and vaccine compositions containing monophosphoryl lipid A |
EP1116029B1 (en) | 1998-09-24 | 2007-12-26 | Promega Corporation | Apoptosis marker antibodies and methods of use |
US8114850B2 (en) * | 1999-04-08 | 2012-02-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US7960540B2 (en) * | 1999-04-08 | 2011-06-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US7314926B1 (en) | 1999-04-08 | 2008-01-01 | Antisoma Research Limited | Antiproliferative activity of g-rich oligonucleotides and method of using same to bind to nucleolin |
JP2002542261A (ja) | 1999-04-15 | 2002-12-10 | メルク フロスト カナダ アンド カンパニー | カスパーゼにより切断されたappを認識する抗体及びその使用法 |
US6165786A (en) | 1999-11-03 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Antisense modulation of nucleolin expression |
JP3869722B2 (ja) | 1999-11-08 | 2007-01-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 細胞死の検出方法及び検出試薬 |
JP2001213804A (ja) | 2000-01-31 | 2001-08-07 | Chugai Pharmaceut Co Ltd | 抗組織因子抗体の複合体 |
EP1272630A2 (en) | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
AU2001249622B2 (en) | 2000-03-30 | 2007-06-07 | Massachusetts Institute Of Technology | RNA sequence-specific mediators of RNA interference |
WO2001091787A1 (en) | 2000-06-02 | 2001-12-06 | University Of Connecticut Health Center | Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
US20020028488A1 (en) | 2000-06-19 | 2002-03-07 | Sujay Singh | Transgenic avian species for making human and chimeric antibodies |
AT411326B (de) | 2000-06-20 | 2003-12-29 | Biering Wolfgang | Hämostatische collagen-pellets |
DE10037861A1 (de) | 2000-08-01 | 2002-02-14 | Max Delbrueck Centrum | Mittel zur Therapie maligner Erkrankungen |
CA2422155A1 (en) | 2000-08-03 | 2002-02-14 | Wim Van Schooten | Production of humanized antibodies in transgenic animals |
RU2322500C2 (ru) | 2000-12-01 | 2008-04-20 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Малые молекулы рнк, опосредующие интерференцию рнк |
GB0100623D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds IV |
IL149701A0 (en) | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
KR100697762B1 (ko) | 2001-07-16 | 2007-03-22 | 아를라 푸즈 에이엠비에이 | 타가토스의 제조 방법 |
AU2002362436A1 (en) | 2001-10-03 | 2003-04-14 | Rigel Pharmaceuticals, Inc. | Modulators of lymphocyte activation and migration |
WO2003087124A2 (en) | 2002-04-05 | 2003-10-23 | The Burnham Institute | Hmgn2 peptides and related melecules that selectively home to tumor blood vessels and tumor cells |
US7357928B2 (en) | 2002-04-08 | 2008-04-15 | University Of Louisville Research Foundation, Inc. | Method for the diagnosis and prognosis of malignant diseases |
US7541150B2 (en) | 2002-04-08 | 2009-06-02 | University Of Louisville Research Foundation, Inc | Method for the diagnosis and prognosis of malignant diseases |
AU2003248724A1 (en) | 2002-06-26 | 2004-01-19 | University Of Louisville Research Foundation, Inc. | A method for the detection of apoptosis |
US20070128117A1 (en) | 2003-02-04 | 2007-06-07 | Bracco International B.V. | Ultrasound contrast agents and process for the preparation thereof |
TW200504210A (en) | 2003-07-30 | 2005-02-01 | Chin-Tarng Lin | A nucleolin antisense inhibiting growth of cancer cell |
US20050187176A1 (en) | 2003-10-10 | 2005-08-25 | Bates Paula J. | Method for inhibiting NF-kappa B signaling and use to treat or prevent human diseases |
MXPA06003768A (es) | 2003-10-17 | 2006-06-23 | Chugai Pharmaceutical Co Ltd | Agente terapeutico para el mesotelioma. |
PL1687066T3 (pl) | 2003-11-14 | 2013-01-31 | Brigham & Womens Hospital Inc | Sposoby modulowania odporności |
AR048210A1 (es) | 2003-12-19 | 2006-04-12 | Chugai Pharmaceutical Co Ltd | Un agente preventivo para la vasculitis. |
CN102539734B (zh) | 2005-05-12 | 2016-02-03 | 清华大学 | 核仁素辅助的癌症诊断与治疗方法 |
WO2007016466A2 (en) | 2005-07-29 | 2007-02-08 | Sloan-Kettering Institute For Cancer Research | Single wall nanotube constructs and uses therefor |
US20090226914A1 (en) | 2007-12-31 | 2009-09-10 | Bates Paula J | Methods and products to target, capture and characterize stem cells |
AU2010202113A1 (en) | 2009-05-25 | 2010-12-09 | Markelee Pty Ltd | Pipe lifting device |
SG10201403147SA (en) | 2009-06-12 | 2014-10-30 | Mannkind Corp | Diketopiperazine microparticles with defined isomer contents |
CN102573613B (zh) * | 2009-10-21 | 2015-07-29 | 健康研究有限公司 | 用于增强肿瘤显像的paa纳米粒子 |
US20110111002A1 (en) * | 2009-11-12 | 2011-05-12 | Calin Viorel Pop | Transport and delivery of glutathione into human cells using gold nanoparticles |
EP2501800A4 (en) * | 2009-11-17 | 2013-05-22 | Musc Found For Res Dev | HUMAN MONOCLONAL ANTIBODIES FOR HUMAN NUCLEOLIN |
US8589851B2 (en) | 2009-12-15 | 2013-11-19 | Memoir Systems, Inc. | Intelligent memory system compiler |
JP5391049B2 (ja) | 2009-12-21 | 2014-01-15 | パナホーム株式会社 | 外壁パネルの施工方法 |
WO2011119058A2 (en) * | 2010-03-22 | 2011-09-29 | Universidade De Coimbra | F3-peptide targeted lipid-based nanoparticles useful for the treatment of angiogenesis-dependent diseases |
US20120107242A1 (en) * | 2010-09-30 | 2012-05-03 | The Board Of Trustees Of The University Of Illinois | Nucleic acid-mediated shape control of nanoparticles for biomedical applications |
EP2497828A1 (en) | 2011-03-07 | 2012-09-12 | Charité - Universitätsmedizin Berlin | Use of aptamers in therapy and/or diagnosis of autoimmune diseases |
PL3446714T3 (pl) | 2011-06-02 | 2021-11-22 | University Of Louisville Research Foundation, Inc. | Nanocząstki sprzężone z cząsteczką skierowaną przeciwko nukleolinie |
US9642805B2 (en) | 2011-11-07 | 2017-05-09 | Northwestern University | Aptamer-loaded, biocompatible nanoconstructs for nuclear-targeted cancer therapy |
EP2982756A1 (en) | 2014-08-04 | 2016-02-10 | Berlin Cures Holding AG | Aptamers for use against autoantibody-associated diseases |
CA3020885A1 (en) | 2015-05-05 | 2016-11-10 | Mohammad Tariq MALIK | Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents |
EP3493852A1 (en) | 2016-08-02 | 2019-06-12 | University of Louisville Research Foundation, Inc. | Targeted nanodroplet emulsions for treating cancer |
EP3545094B1 (en) | 2016-11-23 | 2021-01-27 | Berlin Cures GmbH | Aptamers for use in inhibition and/or suppression of tlr9 activation |
WO2021050779A2 (en) | 2019-09-10 | 2021-03-18 | University Of Louisville Research Foundation, Inc. | Anti-nucleolin agent-peg-conjugated nanoparticles |
US20210299156A1 (en) | 2020-03-28 | 2021-09-30 | Qualigen Inc. | Methods of inhibiting or treating coronavirus infection, and methods for delivering an anti-nucleolin agent |
-
2012
- 2012-06-01 PL PL18185333T patent/PL3446714T3/pl unknown
- 2012-06-01 ES ES15182208.7T patent/ES2690557T3/es active Active
- 2012-06-01 ES ES12730288.3T patent/ES2572915T3/es active Active
- 2012-06-01 WO PCT/US2012/040577 patent/WO2012167173A1/en active Application Filing
- 2012-06-01 DK DK15182208.7T patent/DK3011974T3/en active
- 2012-06-01 US US14/122,617 patent/US9452219B2/en active Active
- 2012-06-01 DK DK18185333.4T patent/DK3446714T3/da active
- 2012-06-01 ES ES18185333T patent/ES2880291T3/es active Active
- 2012-06-01 PT PT181853334T patent/PT3446714T/pt unknown
- 2012-06-01 EP EP15182208.7A patent/EP3011974B1/en active Active
- 2012-06-01 EP EP12730288.3A patent/EP2714094B1/en active Active
- 2012-06-01 EP EP18185333.4A patent/EP3446714B1/en active Active
-
2016
- 2016-08-18 US US15/240,780 patent/US11344633B2/en active Active
-
2022
- 2022-05-11 US US17/741,686 patent/US20220265867A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3011974A1 (en) | 2016-04-27 |
EP2714094B1 (en) | 2016-02-24 |
PL3446714T3 (pl) | 2021-11-22 |
EP3446714A1 (en) | 2019-02-27 |
US11344633B2 (en) | 2022-05-31 |
US20140170076A1 (en) | 2014-06-19 |
US20220265867A1 (en) | 2022-08-25 |
DK3011974T3 (en) | 2018-11-12 |
ES2880291T3 (es) | 2021-11-24 |
WO2012167173A1 (en) | 2012-12-06 |
EP3446714B1 (en) | 2021-03-31 |
US20170095562A1 (en) | 2017-04-06 |
EP2714094A1 (en) | 2014-04-09 |
US9452219B2 (en) | 2016-09-27 |
EP3011974B1 (en) | 2018-08-08 |
PT3446714T (pt) | 2021-06-23 |
DK3446714T3 (da) | 2021-05-10 |
ES2690557T3 (es) | 2018-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2572915T3 (es) | Nanopartículas conjugadas a un agente antinucleolina | |
Yan et al. | Advances in aptamer screening technologies | |
ES2981441T3 (es) | Proteínas de repetición diseñadas que se unen a la seroalbúmina | |
Kim et al. | In vitro selection of RNA aptamer and specific targeting of ErbB2 in breast cancer cells | |
ES2531515T3 (es) | Método para modificar receptores de células T | |
ES2539593T3 (es) | Inmunoglobulinas multivalentes modificadas en la región de bucle estructural | |
JP2016116536A5 (es) | ||
ES2369383T3 (es) | Método auxiliar para diagnosis y terapia de cáncer con nucleolina. | |
Filippi et al. | Aptamer-based technology for radionuclide targeted imaging and therapy: A promising weapon against cancer | |
Kim et al. | PET imaging of HER2 expression with an 18F-fluoride labeled aptamer | |
JP2014113150A5 (es) | ||
JP2012520059A (ja) | プロタンパク質およびその使用方法 | |
CN107207574A (zh) | 血管生成特异性的新型蛋白 | |
Pereira et al. | Aptamers: Novelty tools for cancer biology | |
Perkins et al. | Radiolabelled aptamers for tumour imaging and therapy | |
Zhang et al. | A cell-based single-stranded DNA aptamer specifically targets gastric cancer | |
Cho et al. | Viral nanoparticles decorated with novel EGFL7 ligands enable intravital imaging of tumor neovasculature | |
Barman | Targeting cancer cells using aptamers: Cell-SELEX approach and recent advancements | |
JP2014518624A5 (es) | ||
TW202304971A (zh) | 結合cd71之纖連蛋白iii型結構域 | |
RU2009132631A (ru) | Пептиды, мишенями которых являются кровеносные сосуды злокачественных новообразований легких, и их применения | |
JP2011504361A5 (es) | ||
KR102065112B1 (ko) | 높은 항원 선택성을 갖는 항체의 스크리닝 방법 | |
Vorhies et al. | Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics | |
US20230127087A1 (en) | Glypican-3-specific modified aptamer and use thereof |